Myhre syndrome is an ultra-rare genetic condition caused by specific variants in the SMAD4 gene, leading to progressive tissue fibrosis, short stature, distinctive facial features, joint stiffness, and variable intellectual disability. Fewer than a few hundred cases have been identified worldwide, though diagnoses are increasing as genetic testing becomes more accessible. The syndrome affects nearly every organ system, and its hallmark complication, an exaggerated scarring response in connective tissue, shapes almost every medical decision a patient or family will face.
What Causes Myhre Syndrome
Myhre syndrome results from a change in the SMAD4 gene, which encodes a protein central to how the body regulates growth, tissue repair, and inflammation. The variants responsible are not inherited in the typical sense for most patients; they arise spontaneously (de novo) and are autosomal dominant, meaning only one altered copy of the gene is enough to cause the condition. A large clinic-based series found that the most common variant, affecting the protein at position 500 (p.Ile500Val), accounted for about half of cases, while a variant at position 496 (p.Arg496Cys) accounted for roughly 38%.1PubMed Central. Emergence of the natural history of Myhre syndrome: 47 patients evaluated in the Massachusetts General Hospital Myhre Syndrome Clinic (2016-2023) Two other rarer variants at position 500 make up the rest.
The mechanism is what researchers call a dominant-negative effect. The altered SMAD4 protein does not simply stop working. Instead, it continues to pair with normal copies and other partner proteins but disrupts their ability to function properly. This leads to broad dysregulation of signaling pathways (TGF-β and BMP pathways) that control how the body builds and remodels tissue.2PubMed Central. Myhre syndrome is caused by dominant-negative dysregulation of SMAD4 and other co-factors The result is a body that over-produces fibrous tissue in places it should not, while also failing to regulate normal growth.
How the Condition Unfolds Over Time
Myhre syndrome is not static. Its features evolve as a child grows, and knowing what to expect at each stage can help families and clinicians stay ahead of complications. A natural history study tracking patients across age groups found a fairly consistent pattern.3PubMed Central. Natural history of Myhre syndrome
Growth restriction typically begins before birth and continues after delivery. In the preschool years, neurodevelopmental difficulties appear in a large majority of children, with about 80% showing some form of developmental delay. By school age, the more recognizable physical features become apparent: a distinctive face (often described as a flat midface with a prominent jaw), thickened skin that feels unusually firm, skeletal anomalies, and progressive joint stiffness. Adolescence brings the most serious medical risks, including pulmonary arterial hypertension and narrowing of blood vessels.
The condition also features what is sometimes described as muscle pseudohypertrophy, where muscles appear bulky but do not have normal strength, along with short fingers (brachydactyly) and restricted mobility in the hands, elbows, hips, and other joints.4PubMed. Natural history and life-threatening complications in Myhre syndrome and review of the literature
The Genotype Matters
Not every person with Myhre syndrome experiences it the same way, and emerging evidence suggests that the specific SMAD4 variant plays a meaningful role in severity. Patients with the p.Arg496Cys variant tend to have milder disease: they are less likely to experience hearing loss, growth restriction, and narrowing of the aorta compared to those with variants at position 500.5PubMed Central. Emergence of the natural history of Myhre syndrome: 47 patients evaluated in the Massachusetts General Hospital Myhre Syndrome Clinic (2016-2023) Conversely, the p.Ile500Thr variant appeared to be associated with more severe aortic problems in a small group, though the numbers were too small to draw definitive conclusions.
A study of adults with Myhre syndrome reinforced this pattern, finding that individuals with a codon 500 variant had a more pronounced neurodevelopmental and systemic phenotype overall.6Nature / Europe PMC. Myhre syndrome in adulthood: clinical variability and emerging genotype-phenotype correlations. These correlations are still being refined as more patients are identified, but they already have practical value. A clinician who knows the specific variant can begin to calibrate expectations for which systems need the closest monitoring.
Why Fibrosis Dominates the Clinical Picture
The single most defining feature of Myhre syndrome, and the one that creates the most danger, is an exaggerated fibroproliferative response. Fibrosis is the body’s process of laying down scar tissue, and in Myhre syndrome, that process runs unchecked. This affects the skin (which becomes thick and tight), the joints (which stiffen), the airways (which can narrow), and the cardiovascular system (where blood vessels and heart tissue become progressively fibrotic).
What makes this especially treacherous is that fibrosis can be triggered or dramatically worsened by trauma and surgical procedures. A study documenting surgical outcomes in Myhre syndrome patients found a markedly abnormal fibroproliferative response to intervention in all patients studied, with scar tissue formation severe enough to cause life-threatening complications.7American Journal of Medical Genetics, Part A. Myhre syndrome: Clinical features and restrictive cardiopulmonary complications This response is not limited to surgery; it can also occur spontaneously without any identifiable trigger.8PubMed. Review of the Pathologic Characteristics in Myhre Syndrome: Gain-of-Function Pathogenic Variants in SMAD4 cause a Multisystem Fibroproliferative Response
For families, the practical takeaway is blunt: any surgical procedure, even one that seems routine, carries outsized risks for someone with Myhre syndrome. The recommendation from specialists is to approach surgery with extreme caution, minimizing tissue disruption whenever possible.
Airway and Anesthesia Challenges
One of the most dangerous practical situations for someone with Myhre syndrome is intubation, the insertion of a breathing tube during general anesthesia. The combination of a small midface, limited jaw opening (trismus), an enlarged tongue, and restricted neck movement makes securing the airway extremely difficult. Beyond the initial intubation challenge, patients are prone to developing recurrent subglottic stenosis, a narrowing of the airway below the vocal cords, which often follows an earlier intubation and resists standard treatments.9PubMed. Myhre-LAPS syndrome and intubation related airway stenosis: keys to diagnosis and critical therapeutic interventions
A case report of a 17-year-old girl undergoing dental treatment under general anesthesia illustrates the point. Because of trismus, macroglossia, and difficulty flexing the neck, the anesthesia team had to use a flexible fiber-optic scope to intubate, a technique reserved for known difficult airways.10PubMed Central. Anesthetic Management of a Patient With Myhre Syndrome This is not an unusual complication in Myhre syndrome; it is the expected scenario. Any patient with this diagnosis who needs anesthesia requires a preoperative airway evaluation and a team prepared for difficult intubation. Ideally, the anesthesiologist should be briefed on the syndrome beforehand, since most will never have encountered it.
Cardiovascular Complications
Heart and blood vessel disease is a major source of morbidity in Myhre syndrome. Pulmonary arterial hypertension, where pressure in the blood vessels supplying the lungs becomes dangerously elevated, is among the most serious complications and tends to emerge during adolescence.11PubMed Central. Natural history of Myhre syndrome Narrowing of arteries (vascular stenosis), including the aorta, is also well documented, and as noted earlier, the severity appears to correlate somewhat with the specific SMAD4 variant involved.
Fibrosis can also affect the pericardium, the sac surrounding the heart. In one reported case, a seven-year-old boy with molecularly confirmed Myhre syndrome developed life-threatening recurrent pericarditis along with systemic inflammatory symptoms, requiring treatment with steroids and an interleukin-1 receptor blocker to get the inflammation under control.12Wiley Online Library / PubMed Central. Recurrent pericarditis in Myhre syndrome This case underscores that the inflammatory and fibrotic processes in Myhre syndrome can affect the heart in ways that go beyond structural narrowing of vessels.
Neurodevelopment, Hearing, and Vision
Cognitive and behavioral features are nearly universal in Myhre syndrome, though their severity varies considerably. Developmental delay is the most common neurocognitive finding, followed by autism spectrum disorder.13Genetics in Medicine Open. Neuropsychiatric manifestations in Myhre syndrome: Expanding the phenotype to guide early diagnosis and monitoring Some individuals have mild learning differences, while others have more significant intellectual disability. This variability makes early and ongoing neuropsychological evaluation particularly valuable, since targeted intervention (speech therapy, behavioral support, educational accommodations) can meaningfully affect quality of life when started early.
Hearing loss is common and can be conductive, sensorineural, or mixed. It often goes undiagnosed in younger children unless specifically screened for, and since hearing problems compound developmental delay, routine audiology assessments are standard in management guidelines. Vision can also be affected. A case report documented novel ocular and inner ear anomalies in a patient with Myhre syndrome, further expanding the known sensory profile of the condition.14PubMed Central. Novel Ocular and Inner Ear Anomalies in a Patient with Myhre Syndrome
Conditions That Can Be Confused with Myhre Syndrome
Because Myhre syndrome is so rare, many patients wait years for the correct diagnosis. Several other conditions share overlapping features. Acromicric dysplasia also involves short stature, thickened skin, and joint stiffness, but it lacks the intrauterine growth restriction, intellectual disability, and severity of skin and muscle involvement seen in Myhre syndrome. Geleophysic dysplasia is another look-alike, characterized by short stature, short hands and feet, and distinctive facial features, but it is typically associated with organ enlargement, which is uncommon in Myhre syndrome.15Annals of Pediatric Endocrinology & Metabolism. Myhre syndrome: the first case in Korea Weill-Marchesani syndrome is also in the differential, though it tends to be more strongly associated with eye problems like ectopia lentis.
In practice, genetic testing has become the definitive tiebreaker. Targeted sequencing of SMAD4 or broader exome sequencing can confirm the diagnosis and distinguish Myhre syndrome from these close mimics. Given the implications for surgical risk and monitoring, getting the correct molecular diagnosis matters more here than in many genetic conditions.
Approaches to Treatment
There is currently no approved therapy that targets the underlying cause of Myhre syndrome, but early evidence for one approach has generated cautious optimism. A pilot clinical trial tested losartan, a blood pressure medication that also happens to reduce TGF-β signaling, in three patients with Myhre syndrome. After 12 months, skin fibrosis improved significantly, joint range of motion increased (particularly in the upper and lower arms), and cardiac fibrosis showed improvement in one patient with a positive trend in the others.16PubMed Central. A pilot clinical trial with losartan in Myhre syndrome These are very small numbers, and a pilot trial is far from a definitive answer, but the results were encouraging enough to suggest that modulating the fibrotic pathway pharmacologically can make a difference.
Growth is another area where targeted intervention has shown promise. Short stature in Myhre syndrome does not respond well to growth hormone alone, but a case report documented improved height in a boy treated with growth hormone combined with letrozole, an aromatase inhibitor that delays bone maturation.17Frontiers in Pediatrics (via Europe PMC). Case Report: Improved Height in a Patient With Myhre Syndrome Using a Combination of Growth Hormone and Letrozole This remains a single case report, so it is far too early to call it a standard strategy, but it illustrates that creative approaches can sometimes work when standard growth treatment falls short.
Beyond these experimental approaches, current management is largely about surveillance and early intervention for specific complications: regular cardiac imaging, pulmonary function testing, audiology screening, developmental assessments, and careful coordination before any surgical procedure.
Cancer Risk
SMAD4 has a complicated relationship with cancer. Loss-of-function variants in SMAD4 are a well-known cause of juvenile polyposis syndrome, a condition that predisposes to gastrointestinal tumors. The gain-of-function variants in Myhre syndrome are biologically different, but there is growing concern that they too may carry cancer risk. A review of 61 patients found that about 10% had developed some form of neoplasia, and endometrial cancer was disproportionately common among female patients, occurring in roughly 9% at a relatively young average age of 40.18PubMed Central. Gain-of-function pathogenic variants in SMAD4 are associated with neoplasia in Myhre syndrome
This does not mean that every patient with Myhre syndrome will develop cancer, but the numbers are high enough to warrant attention. Clinicians managing adults with the condition should have cancer surveillance on their radar, particularly gynecologic screening for female patients. The evidence is still being gathered, and formal screening guidelines have not yet been established, but awareness alone can lead to earlier detection.
Myhre Syndrome in Adulthood
For a long time, almost everything known about Myhre syndrome came from pediatric reports, leaving adults and their clinicians with little guidance. That is beginning to change. A study of 24 adults with the condition, including 17 who were not diagnosed until after age 18, found that the adult cohort generally had a milder phenotype and lower mortality rates than what the pediatric literature had suggested.19Nature / Europe PMC. Myhre syndrome in adulthood: clinical variability and emerging genotype-phenotype correlations. This may partly reflect a diagnostic bias: the most severely affected patients are identified in childhood, while milder cases slip through until genetic testing catches them later in life.
The finding is still reassuring. It means that Myhre syndrome encompasses a wider clinical spectrum than originally appreciated, and that some adults live with manageable symptoms for decades before anyone connects the dots. Late diagnosis is also a reminder that many clinicians outside of genetics do not recognize the condition. Adults who have unexplained short stature, stiff joints, thick skin, and a history of developmental difficulties may benefit from SMAD4 testing even if no one has previously suspected a syndromic diagnosis.
Prenatal Detection
Myhre syndrome can occasionally be identified before birth, though the prenatal picture is subtle and nonspecific. Reported prenatal features include severe intrauterine growth restriction and congenital heart defects, including a case with pulmonary atresia and ventricular septal defect, a form of tetralogy of Fallot. Mild facial dysmorphism, such as a wide nasofrontal angle, has also been described on ultrasound. In these cases, next-generation sequencing of fetal DNA confirmed the SMAD4 variant.20PubMed Central. Prenatal Diagnosis of Myhre Syndrome in Two Cases: Further Delineation of the Cardiac and External Phenotype
Prenatal detection remains the exception rather than the rule. Most pregnancies affected by Myhre syndrome are not identified until after birth, when the constellation of features becomes more recognizable. Still, for families with a known variant or pregnancies with unexplained growth restriction plus cardiac anomalies, fetal genetic testing is worth discussing with a geneticist.
The Research and Advocacy Landscape
For such a rare condition, the organized research effort around Myhre syndrome is remarkably active. The Myhre Syndrome Foundation created a patient registry in collaboration with the Coordination of Rare Diseases at Sanford, capturing disease symptoms and quality-of-life data from 105 people with Myhre syndrome across 24 countries.21PubMed. Descriptive Epidemiology From the Myhre Syndrome Foundation Registry: The Value of Self-Reported Data Self-reported data from registries like this may lack the rigor of clinic-based studies, but they dramatically expand the available knowledge base for a condition where most clinical series include fewer than 50 patients.
On the drug development side, the Myhre Syndrome Foundation has prioritized fibrosis and stenosis alongside autism and intellectual disability as the two burdens that matter most to patients and families. Their strategy includes building a preclinical screening platform using patient-derived and animal models, developing clinical trial infrastructure adapted for ultra-rare diseases (where traditional trial designs often fail), and identifying new therapeutic targets by studying how SMAD4 variants rewire protein interactions in key signaling pathways.22PubMed Central. Navigating Drug Discovery for Myhre Syndrome: The Complexity of a Multisystemic Rare Disease Partnerships with regulatory authorities and industry are part of the plan, acknowledging that patient advocacy alone cannot move the needle without institutional buy-in. For families newly facing a Myhre syndrome diagnosis, connecting with the Foundation and its registry is one of the most immediately useful steps available.